Clinical trials: Stage I Prostate Cancer
Prostate Cancer
A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer
The purpose of this clinical study is to assess the safety and tolerability of BMS-641988 once daily orally in Japanese patients with castration resistant prostate cancer
- Trial name
- NCT00644488
- Testing
- BMS-641988 (AR#2)
- Where
- 3 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer, Cognitive/Functional Effects
Psychosocial Adjustment After Radiation Therapy in Patients With Cancer
RATIONALE: Gathering information about psychological and social adjustment after radiation therapy in patients with cancer may help doctors plan the best treatment.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer
- Trial name
- NCT00905086
- Testing
- questionnaire administration, cognitive assessment, psychosocial assessment and care
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Castration-resistant Prostate Cancer
Safety of Prodencel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)
This phase I clinical trial is to evaluate the safety of Prodencel (an autologous dendritic cell therapeutic tumor vaccine.) in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT05533203
- Testing
- Prodencel; an autologous dendritic cell therapeutic tumor vaccine
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Humantech Biotechnology Co. Ltd
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
The goal of this clinical trial is to find out if taking natural products green tea and quercetin along with docetaxel chemotherapy improves the therapy of advanced prostate cancer, i.e., metastatic castration-resistant prostate…
- Trial name
- NCT06615752
- Testing
- green tea and quercetin + docetaxel
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Charles Drew University of Medicine and Science
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Prostate Cancer
A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection in Participants With Prostate Cancer
This is a phase 1 study to assess the safety and tolerability of SHR-6914 as monotherapy therapy in adult subjects with prostate cancer.
- Trial name
- NCT07735377
- Testing
- SHR-6914
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Neoplasms
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive…
- Trial name
- NCT02635672
- Testing
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda
- Where
- 16 sites in United States, Chile and 1 more
- Volunteers
- 110 people
- Sponsor
- Vincerx Pharma, Inc.
Prostate Cancer
Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets For High Risk Prostate Cancer
Since high risk prostate cancer requires higher radiation, this study is being done to determine the maximum tolerated dose of radiation to the prostate and pelvic regions.
- Trial name
- NCT02353819
- Testing
- Stereotactic Ablative Radiotherapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
Prostate Cancer
Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer
20 patients with invasive castration resistant prostate cancer and radiologically verified metastases will be enrolled into the Phase I Clinical Trial. The trial is a dendritic cell based immunotherapy.
- Trial name
- CryoIT (NCT02423928)
- Testing
- Dendritic cell based cryoimmunotherapy, Cyclophosphamide, ipilimumab
- Where
- Norway
- Volunteers
- 18 people
- Sponsor
- Alden Cancer Therapy II
Prostate Cancer
Hypo-fractionated Postoperative IMRT in Prostate Cancer
To report the outcome of hypo-fractionated radiotherapy after radical prostatectomy (RP) for prostate cancer (PCa) using IMRT-SIB.
- Trial name
- NCT03233672
- Testing
- Hypo-fractionated postoperative IMRT-SIB
- Volunteers
- 124 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Urothelial Cancer, Bladder Cancer
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
Background: Genitourinary cancers are some of the most common types of cancer. They are lethal when they spread. The drug M7824 blocks the paths that cancer cells use to stop the immune system from fighting cancer.
- Conditions
- Urothelial Cancer, Bladder Cancer, Genitourinary Cancer, Urogenital Neoplasms
- Trial name
- NCT04235777
- Testing
- Stereotactic body radiation therapy (SBRT), PDS01ADC, M7824
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer.
- Trial name
- ANDROMEDA (NCT07336446)
- Testing
- AZD9750, AZD5305
- Where
- 5 sites in United States, Australia and 2 more
- Volunteers
- 6 people
- Sponsor
- AstraZeneca
Prostate Cancer
Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00293371
- Testing
- docetaxel, prednisone, vatalanib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Acupuncture Treatment for Hot Flashes Study
Patients with prostate cancer who are / were treated with hormonal treatment and developed hot flashes as a side effect are offered Acupuncture as an investigational intervention.
- Trial name
- NCT00421902
- Testing
- Acupuncture
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- New York Presbyterian Brooklyn Methodist Hospital
Prostate Cancer
Study in Predicting Outcome of Patients Undergoing Radiation Therapy for Prostate Cancer
RATIONALE: Proteins found in blood and urine samples may help predict outcome and allow doctors to plan more effective treatment.
- Trial name
- NCT00045331
- Testing
- proteomic profiling
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7, Stage II Prostate Adenocarcinoma AJCC v7
Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
This phase I trial studies stereotactic body radiation therapy (SBRT) in treating patients with prostate cancer that is likely to come back or spread (high-risk) undergoing surgery.
- Conditions
- Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT02830165
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Jonsson Comprehensive Cancer Center
PSA Level Less Than or Equal to Fifteen, PSA Level Less Than Ten
Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance
This randomized phase II trial studies pomegranate-extract pill in preventing tumor growth in patients with prostate cancer that is limited to a certain part of the body (localized), who have chosen observation as their treatment…
- Conditions
- PSA Level Less Than or Equal to Fifteen, PSA Level Less Than Ten, Stage I Prostate Cancer AJCC v7, Stage II Prostate Cancer AJCC v7
- Trial name
- NCT02095145
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Pomegranate-Extract Pill
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Bone Metastases
A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases
This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer and bone metastases
- Trial name
- NCT00757757
- Testing
- MCS110
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Adenocarcinoma of the Prostate
First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients.
This open label, dose escalating study is a phase I/IIa first in man study designed to evaluate the safety and tolerability of intratumoral administration of a novel oncolytic adenovirus (ORCA-010) in treating diagnosed treatment…
- Trial name
- NCT04097002
- Testing
- ORCA-010
- Where
- 5 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Orca Therapeutics B.V.
Prostate Cancer
SBRT in 4 Fractions for Prostate Cancer
This is a prospective multicentric phase-I-II pilot feasibility study. The main objective is to study early and late side effects of hypofractionated accelerated RT for prostate cancer with FFF (Free Flattened Filter) beam.
- Trial name
- NCT03873090
- Testing
- SBRT
- Volunteers
- 33 people
- Sponsor
- Istituto Clinico Humanitas